Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28652870 | 0.78 | PFKFB3 (0.71) | PFKFB3PFKFB4 | |
| SCHEMBL787888 | 0.75 | PFKFB3 (1.00) | PFKFB3PFKFB4 | |
| SCHEMBL30268334 | 0.75 | PFKFB3 (1.00) | PFKFB3PFKFB4 | |
| SCHEMBL21857359 | 0.75 | PFKFB3 (1.00) | PFKFB3PFKFB4 | |
| SCHEMBL794120 | 0.75 | PFKFB3 (0.71) | PFKFB3PFKFB4 | |
| SCHEMBL788169 | 0.75 | PFKFB3 (1.00) | PFKFB3PFKFB4 | |
| SCHEMBL12474851 | 0.75 | PFKFB3 (0.66) | PFKFB3PFKFB4 | |
| SCHEMBL30268397 | 0.74 | PFKFB3 (1.00) | PFKFB3PFKFB4 | |
| SCHEMBL15086536 | 0.74 | PFKFB3 (1.00) | PFKFB3PFKFB4 | |
| SCHEMBL787879 | 0.74 | PFKFB3 (1.00) | PFKFB3PFKFB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| EP-2616450-A2 | SULFONAMIDE COMPOUNDS | Kancera AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | SULT1A1, STS, ARSA | PFKFB3 952/4885PFKFB4 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.